Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (March 23 – March 29)

/ By / Copyright, Design, Others, Patent, Trademark

Almost at the end of March with a post on the wonder drug Semaglutide’s patent expiry and its impact in India. Post on the Calcutta HC’s judgment removing subject-matter objections to the registration of GUIs as a design under the Designs Act. Another post on the government-led blocking of 3100+ Telegram channels marking a significant shift in India’s intermediary liability regime and censorship architecture. Case summaries and IP developments from the country and the globe and much more in this

SpicyIP Weekly Review (March 23 – March 29) Read More »

The Madras High Court’s Injunction in Sreedevi v. SaReGaMa: Was the Supreme Court Right to Stay It?

/ By / Copyright

In Sreedevi Video Corporation v. SaReGaMa India Ltd., the Madras High Court took the unusual step of allowing an injunction claim to proceed even after holding the plaintiff’s claim to copyright ownership as time-barred. The Supreme Court has since stayed this ruling, signalling concerns with this separation of remedies. Shubham Thakare examines whether an injunction can truly survive a limitation bar on ownership, and the broader implications for copyright disputes under the Copyright Act and limitation law.  Shubham is a

The Madras High Court’s Injunction in Sreedevi v. SaReGaMa: Was the Supreme Court Right to Stay It? Read More »

A New Shield for the “Strike” Era? Analysing the Delhi High Court’s Reasoning in Associated Broadcasting v. Google

/ By / Copyright

In Associated Broadcasting Company v. Google, the Delhi High Court offers a respite to content creators against copyright strikes through Section 60 of the Copyright Act, 1957. Shubham Thakare explains the decision and how it provides creators with a meaningful, if limited, tool to challenge abusive copyright strikes. Shubham is a third-year B.A., LL.B. (Hons.) student at the National Law School of India University, Bengaluru, with an interest in copyright and trademark law. A New Shield for the “Strike” Era?

A New Shield for the “Strike” Era? Analysing the Delhi High Court’s Reasoning in Associated Broadcasting v. Google Read More »

Sahyog or Suppression? The New Architecture of Intermediary Liability

/ By / Others

The recent government-led blocking of 3100+ Telegram channels marks a significant shift in India’s intermediary liability regime and censorship architecture. Priyam Mitra examines how this move and the newly created Sahyog Platform erode due process and free speech safeguards. Priyam is a third-year student at NLSIU, Bengaluru, and is deeply interested in IP and Data Protection laws. His previous posts can be accessed here. Sahyog or Suppression? The New Architecture of Intermediary Liability By Priyam Mitra Telegram has been the subject

Sahyog or Suppression? The New Architecture of Intermediary Liability Read More »

[SpicyIP Tidbit] Patent’s Gone, War’s On: Inside Novo Nordisk’s Semaglutide Litigation Blitz

/ By / Patent, Trademark

Yesterday, Khushi and I wrote on the Semaglutide patent expiry and what it could mean for Indian generic companies and the general public. And while the market is seeing more affordable versions of the drug, a separate story is taking place in the Delhi High Court with Novo Nordisk filing a fresh set of trademark and patent infringement suits against generic companies.  The Ozempic Name Game: Novo Nordisk v. DRL Round 2 On Semaglutide injections, Novo Nordisk has filed a

[SpicyIP Tidbit] Patent’s Gone, War’s On: Inside Novo Nordisk’s Semaglutide Litigation Blitz Read More »

Wonder Drug, Generic Price: What Semaglutide’s Patent Expiry Should Really Mean for India

/ By / Patent

[This post is co-authored with Khushi Krishania. Khushi is a third-year B.Sc. LL.B. (Hons.) {Cybersecurity} student at the National Law Institute University, Bhopal, with a particular interest in the intersection of copyright and data protection law.] Christmas came early for Indian generic manufacturers as the Indian patent on Semaglutide, a potent GLP-1 receptor agonist, expired on March 20. The drug is commercially sold by Novo Nordisk as Ozempic and Wegovy and is used to manage type-2 diabetes and obesity. After

Wonder Drug, Generic Price: What Semaglutide’s Patent Expiry Should Really Mean for India Read More »

GUIs Join the Design Club!

/ By / Design

Disclaimer: Used Claude AI to make stylistic changes to the post. Any mistakes made are all mine alone. Calcutta High Court’s recent decision in  NEC Corporation v. Controller (NEC Corp) opens up the option of design protection for Graphic User Interface (GUI) dismissing for the second time the subject matter objections raised by the IPO. The decision to expand design protection to GUIs, as we will see, creates doctrinal inconsistency, as the Delhi HC in two decisions (Hulm Entertainment and

GUIs Join the Design Club! Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (March 16 – March 22)

/ By / Copyright, Geographical Indication, Others, Patent, Trademark

(This week’s review is authored by Shubham Thakare. Shubham is currently an intern with SpicyIP. He is a third-year B.A., LL.B. (Hons.) student at the National Law School of India University, Bengaluru, with an interest in copyright and trademark law.) As we move further into March, this week’s review brings into focus questions around the limits of IP protection over identity, alongside a series of significant judicial developments across trademarks, patents, and copyright. From clarifying the misplaced claim of copyright

SpicyIP Weekly Review (March 16 – March 22) Read More »

SpicyIP Bells & Whistles: IP Events and Opportunities (23.03.2026)

/ By / Courses & Workshops, Opportunities

Welcome back to another week of Bells & Whistles. As always, we’ve rounded up a mix of developments, opportunities, and thoughtful reads from across the IP world along with a Bell of the Week that’s well worth revisiting. Bell of the Week: The Internet Some bells do not just chime, they connect. Lately, I’ve been thinking about how people search for answers when the usual systems fail them. In Diagnosis, based on Lisa Sanders’ column in The New York Times, patients with rare,

SpicyIP Bells & Whistles: IP Events and Opportunities (23.03.2026) Read More »

TWN- IUCIPRS Workshop on Patent Opposition in Pharmaceutical Field (Apply by 31 March)

/ By / Courses & Workshops, Patent

Inter-University Centre for IPR Studies (IUCIPRS), CUSAT, and Third World Network are organising the 7th edition of their workshop titled ‘Patent Opposition in the Pharmaceutical Field’ from 28 May- 1 June, 2026. Last date to apply is 31 March, 2026. Read on below for their announcement. TWN- IUCIPRS Workshop on Patent Opposition in Pharmaceutical Field (Apply by 31 March) Inter-University Centre for IPR Studies (IUCIPRS), CUSAT, and Third World Network are collaboratively organising the seventh edition of the workshop titled ‘Patent Opposition in

TWN- IUCIPRS Workshop on Patent Opposition in Pharmaceutical Field (Apply by 31 March) Read More »

Scroll to Top